Locked vault There are a number of factors that work against a more efficient drug distribution system, including industry privacy agreements that mask financial incentives. (Image: Shutterstock)

The current supply chain for pharmaceuticals has built-in incentives to include low-value, high-cost drugs, a new study finds. For employer-sponsored plans and other purchasers, wasteful spending on such drugs represent significant costs that could be reduced if purchasers pushed for more efficiency.

The study by the Commonwealth Fund, looked at drug utilization data from 15 self-insured plan sponsors, including 13 members of the Pacific Business Group on Health (PBGH) and estimated savings from cutting back on low-value, high-cost drugs.

Complete your profile to continue reading and get FREE access to BenefitsPRO.com, part of your ALM digital membership.

Your access to unlimited BenefitsPRO.com content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical BenefitsPRO.com information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

Already have an account?



Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2023 ALM Global, LLC. All Rights Reserved.